

# Mealplanner and MediSapiens receive EU grant for joint project to prevent the onset of diabetes

*The Mealplanner partners with MediSapiens in EU funded program to develop an app that helps users prevent the onset of type 2 diabetes*

PORI, PORI, FINLAND, January 5, 2018

[/EINPresswire.com/](http://EINPresswire.com/) -- The

Mealplanner™ Europe Oy, a Finnish MedTech company creating software that plans and organizes nutrition for users, and MediSapiens, a leading developer and provider of genomic, biomedical and health data solutions, have partnered to develop an application for helping users in the prevention of onset of type 2 [diabetes](#). The development is funded by an EU grant from the PERMIDES (Personalised Medicine Innovation through Digital Enterprise Solutions) project.



The joint project aims at developing a novel application which helps users to assess the risk of developing type 2 diabetes and plan their nutrition in order to prevent the onset of diabetes. The application will be built to utilize novel AI-based methods for risk assessment. The projected launch of the application is during the second quarter of 2018.

“We’re thrilled to engage in this development with a solid, science-backed company working in the emerging field of personalized nutrition. This highlights our commitment to work for better future health through better and more efficient use of data. Type 2 diabetes is a global threat to rising incidence, and the potential healthcare cost savings of prevention of Type 2 diabetes are substantial.” says Marko Kuisma, CCO of MediSapiens.

Type 2 diabetes has reached epidemic levels in the world population, including an alarming proportion of children. Indicative is that globally, nearly 28% of women aged 30-45 are diabetic. The focus of primary healthcare concentrates on treating the symptoms of the disease rather than prevention even though Type 2 diabetes can be reversed through proper diet, exercise and medication. The technology being developed by The Mealplanner and MediSapiens is designed to prevent Type 2 diabetes rather than treat it after it has occurred.

## About The Mealplanner

The Mealplanner Oy is a Finnish MedTech company. We create coherent software that can plan and organize optimum nutrition for our customers. Our mission is to bring back nutrition as part of medicine; in fact, many diet-related diseases can be cured and prevented by healthy nutrition. We also provide corporate wellness services to help our clients maintain a healthy workforce. To follow this and other news about The Mealplanner please visit The Mealplanner website [TheMealplanner.com](http://TheMealplanner.com)

Contact The Mealplanner:  
Stefan Repin, CMO  
stefan@themealplanner.com  
themealplanner.com

#### About MediSapiens

MediSapiens Ltd. is a bioinformatics company specialized in pharmaceutical research and translational genomics, providing pharmaceutical and biomedical research organizations with tools that help them design more effective personalized drugs against life-threatening diseases. Established in 2009 and based in Helsinki, Finland, and Cambridge, Massachusetts, MediSapiens creates intuitive software platforms to manage, integrate, and visualize complex multi-dimensional datasets, such as genomic sequencing data. The company's goal is to drive medicine forward by developing tools that provide scientists with a way to quickly analyze and visualize vast amounts of data and turn it into knowledge that fuels innovation.

Contact MediSapiens:  
Marko Kuisma, CCO  
marko.kuisma@medisapiens.com  
[www.medisapiens.com](http://www.medisapiens.com)

Stefan Repin  
The Mealplanner  
0036308864314  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.